1. Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab 
William J. Sandborn, Maria T. Abreu, Geert D'Haens, Jean–Frédéric Colombel, Severine Vermeire, Krassimir Mitchev, Corinne Jamoul, Richard N. Fedorak, Martina E. Spehlmann, Douglas C. Wolf, Scott Lee, Paul Rutgeerts 
Clinical Gastroenterology and Hepatology 
Volume 8, Issue 8, Pages e2 (August 2010)
DOI: /j.cgh
Copyright © 2010 AGA Institute Terms and Conditions

2. Supplementary Figure 1
Study flow diagram. ae, adverse event; loe, lack/loss of efficacy; ltfu, lost to follow-up evaluation; q2w, every 2 weeks; q4w, every 4 weeks; woc, withdrawal of consent.
Clinical Gastroenterology and Hepatology 2010 8, e2DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

3. Figure 1
Response and remission rates (A) over the open-label induction phase (n = 539) and (B) at week 26 (n = 329).
Clinical Gastroenterology and Hepatology 2010 8, e2DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

4. Figure 2 CDAI scores over time (n = 329).
Clinical Gastroenterology and Hepatology 2010 8, e2DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions